Cargando…

The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide and has a poor prognosis. Sorafenib, the only targeted therapeutic agent for HCC, is a multiple kinase inhibitor with targets including RAF and VEGFR-2/3 that display a very limited ability to extend the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Wanting, Xia, Hongwei, Zhou, Sheng, Fan, Zhenhai, Xu, Huanji, Gong, Qiyong, Nie, Yongzhan, Tang, Qiulin, Bi, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799119/ https://www.ncbi.nlm.nih.gov/pubmed/35116864 http://dx.doi.org/10.21037/tcr.2019.07.11

Ejemplares similares

ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells
por: Zhou, Sheng, et al.
Publicado: (2018)

MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells
por: Xu, Huanji, et al.
Publicado: (2019)

Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis
por: Ren, Meiling, et al.
Publicado: (2021)

Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation
por: Yu, Huangfei, et al.
Publicado: (2017)

Cholesterol activates the Wnt/PCP-YAP signaling in SOAT1-targeted treatment of colon cancer
por: Xu, Huanji, et al.
Publicado: (2021)

Inhibition of stress proteins TRIB3 and STC2 potentiates sorafenib sensitivity in hepatocellular carcinoma
por: Zhou, Sheng, et al.
Publicado: (2023)

EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy
por: Xia, Hongwei, et al.
Publicado: (2018)

Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment
por: Ye, Di, et al.
Publicado: (2021)

Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition
por: Zhang, Chenliang, et al.
Publicado: (2022)

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
por: Chen, Yunching, et al.
Publicado: (2017)

Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
por: Chen, John Chun-Hao, et al.
Publicado: (2016)

Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells
por: Zhang, Yunjie, et al.
Publicado: (2018)

DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells
por: Chen, Zhangqian, et al.
Publicado: (2023)

Inhibition of ISG15 Enhances the Anti-Cancer Effect of Trametinib in Colon Cancer Cells
por: Zhou, Sheng, et al.
Publicado: (2019)

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway
por: Du, Wei, et al.
Publicado: (2012)

RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma
por: Bai, Xue-Song, et al.
Publicado: (2020)

Casp8 acts through A20 to inhibit PD‐L1 expression: The mechanism and its implication in immunotherapy
por: Zou, Jiahuan, et al.
Publicado: (2021)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway
por: Song, Ye, et al.
Publicado: (2021)

Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways
por: Cui, Shu-Xiang, et al.
Publicado: (2016)

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients
por: Zhu, Gongmin, et al.
Publicado: (2021)

Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer
por: Ma, Ji, et al.
Publicado: (2020)

Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis
por: Zhang, Huan, et al.
Publicado: (2021)

Regulation of Ferroptosis by Amino Acid Metabolism in Cancer
por: Yang, Jian, et al.
Publicado: (2022)

Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy
por: Zou, Yuheng, et al.
Publicado: (2022)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

In Vitro and In Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis
por: Cheng, Zhe, et al.
Publicado: (2020)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways
por: Wang, Yu, et al.
Publicado: (2016)

Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation
por: Sheng, Jun, et al.
Publicado: (2021)

CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway
por: Chen, Erbao, et al.
Publicado: (2023)

A Positive Feedback Loop of lncRNA HOXD-AS2 and SMYD3 Facilitates Hepatocellular Carcinoma Progression via the MEK/ERK Pathway
por: Sun, Jin, et al.
Publicado: (2023)

Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis
por: Nie, Tao, et al.
Publicado: (2016)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes
por: Thomas, Kubin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q46kd35fv9p3rsgk1fnaf9i0bu